Gene Therapy for Cancer
Gene Therapy for Solid Tumors
Gene therapy for solid tumors is advancing more slowly than for blood cancers due to two challenges: physical accessibility of tumors embedded in tissue, and the immunosuppressive tumor microenvironment that disables T-cells on arrival. Active approaches include CAR-T engineered to resist suppression, gene-modified TIL therapy, direct in vivo gene delivery, and oncolytic virus therapy (T-VEC approved for melanoma). Patients with HER2, mesothelin, GD2, or EGFR-expressing tumors have the most relevant active programs.
Read guide